KYMR
Kymera Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.09B
P/E Ratio
—
EPS
$-3.58
Beta
2.03
52W High
$103.00
52W Low
$36.65
50-Day MA
$82.85
200-Day MA
$72.61
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | $51.48M |
| Gross Profit (TTM) | $-283.00M |
| EBITDA | $-348.58M |
| Operating Margin | -244.90% |
| Return on Equity | -27.10% |
| Return on Assets | -17.20% |
| Revenue/Share (TTM) | $0.58 |
| Book Value | $18.73 |
| Price-to-Book | 4.60 |
| Price-to-Sales (TTM) | 137.75 |
| EV/Revenue | 126.58 |
| EV/EBITDA | -9.49 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 55.50% |
| Shares Outstanding | $82.26M |
| Float | $55.03M |
| % Insiders | 2.10% |
| % Institutions | 117.63% |
Historical Volatility
HV 10-Day
71.20%
HV 20-Day
54.85%
HV 30-Day
49.05%
HV 60-Day
43.83%
HV Rank
63.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($119.43 target)
5
Strong Buy18
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026